Novartis Opens Door to Broad Dealmaking in RNAi
This article was originally published in Start Up
Executive Summary
Novartis has seemingly changed the RNAi therapeutics game with its potential blockbuster deal with Alnylam, suggesting that getting to the bottom of RNAi's therapeutic possibilities requires significant assets and staying power.
You may also be interested in...
Sanofi Moves into MicroRNA, Signs Preclinical Platform Deal with Regulus
With $25 million upfront, $10 million in equity and hundreds of millions of dollars in possible milestones, Sanofi makes a significant early bet on the latest RNA-based therapeutic class to emerge.
Sanofi Moves into MicroRNA, Signs Preclinical Platform Deal with Regulus
With $25 million upfront, $10 million in equity and hundreds of millions of dollars in possible milestones, Sanofi makes a significant early bet on the latest RNA-based therapeutic class to emerge.
Isis: Pondering Platform Power
The January 2008 collaboration Isis forged with Genzyme was transformative for Isis and a desperately sought-after validation of the antisense field. But unlike its brethren in oligonucleotide drug development -- and most biotechs, for that matter -- Isis rejects the notion of commercializing its products. The deal sets up a paradox: Can Isis remain a platform company once investors' focus is on a product and its trajectory? In a sense, can it stay small?